Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Dreyling

Showing results (131-140 of 336) with videos related to

Pageof 34
Sort By:
Leukemia & Lymphoma|April 15, 2014
Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's macroglobulinemiaIsabelle Herth, Manfred Hensel, Michael Rieger, et al.
Hemasphere|November 15, 2019
Maintenance Treatment for Patients With Mantle Cell Lymphoma: A Systematic Review and Meta-analysis of Randomized TrialsLiat Vidal, Anat Gafter-Gvili, Martin Dreyling, et al.
Hemasphere|July 11, 2022
Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in GermanyDaniela Skalt, Bernhard Moertl, Michael von Bergwelt-Baildon, et al.
Blood|March 18, 2025
Prognostic Biomarkers in MCL: Insights from the SHINE Trial on the impact of MCL35 score and TP53 Mutation StatusCiara L Freeman, Srimathi Srinivasan, Brendan Hodkinson, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 18, 2011
Treatment of indolent lymphoma in Germany - results of a representative population-based surveyChristian Schmidt, Sebastian Fetscher, Christian Görg, et al.
Hematological Oncology|June 10, 2023
Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimusMarie Moosburner, Lamija Alibegovic, Korbinian Hasselmann, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2021
Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell LymphomaMatthew J Matasar, Martin Dreyling, Sirpa Leppä, et al.
Frontiers in Neurology|April 12, 2021
CXCL13 and CXCL9 CSF Levels in Central Nervous System Lymphoma-Diagnostic, Therapeutic, and Prognostic RelevanceIlias Masouris, Kirsi Manz, Markus Pfirrmann, et al.
British Journal of Haematology|July 16, 2010
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphomaFrancesco d'Amore, John Radford, Thomas Relander, et al.
Leukemia & Lymphoma|August 5, 2011
Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemiaTobias Herold, Till Seiler, Rupert Egensperger, et al.
Pageof 34

Showing results (131-140 of 336) with videos related to

Sort By:
Pageof 34
Leukemia & Lymphoma|April 15, 2014
Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's macroglobulinemiaIsabelle Herth, Manfred Hensel, Michael Rieger, et al.
Hemasphere|November 15, 2019
Maintenance Treatment for Patients With Mantle Cell Lymphoma: A Systematic Review and Meta-analysis of Randomized TrialsLiat Vidal, Anat Gafter-Gvili, Martin Dreyling, et al.
Hemasphere|July 11, 2022
Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in GermanyDaniela Skalt, Bernhard Moertl, Michael von Bergwelt-Baildon, et al.
Blood|March 18, 2025
Prognostic Biomarkers in MCL: Insights from the SHINE Trial on the impact of MCL35 score and TP53 Mutation StatusCiara L Freeman, Srimathi Srinivasan, Brendan Hodkinson, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 18, 2011
Treatment of indolent lymphoma in Germany - results of a representative population-based surveyChristian Schmidt, Sebastian Fetscher, Christian Görg, et al.
Hematological Oncology|June 10, 2023
Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimusMarie Moosburner, Lamija Alibegovic, Korbinian Hasselmann, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2021
Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell LymphomaMatthew J Matasar, Martin Dreyling, Sirpa Leppä, et al.
Frontiers in Neurology|April 12, 2021
CXCL13 and CXCL9 CSF Levels in Central Nervous System Lymphoma-Diagnostic, Therapeutic, and Prognostic RelevanceIlias Masouris, Kirsi Manz, Markus Pfirrmann, et al.
British Journal of Haematology|July 16, 2010
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphomaFrancesco d'Amore, John Radford, Thomas Relander, et al.
Leukemia & Lymphoma|August 5, 2011
Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemiaTobias Herold, Till Seiler, Rupert Egensperger, et al.
Pageof 34